Avalo Therapeutics Ownership 2024 | Who Owns Avalo Therapeutics Now?
Institutional Ownership
61.50%
Insider Ownership
16.46%
Retail Ownership
22.04%
Institutional Holders
42.00
Avalo Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 46.93% | 0.11% | 4,415,000 | 450,334 | 11.36% | 7,726,250,000 | Mar 31, 2023 |
| POINT72 ASSET MANAGEMENT, L.P. | 11.70% | 0.01% | 1,100,737 | 600,000 | 119.82% | 1,926,290,000 | Mar 31, 2023 |
| VR ADVISER, LLC | 10.63% | 0.34% | 1,000,000 | 1,000,000 | 100.00% | 1,750,000,000 | Mar 31, 2023 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 8.60% | 0.11% | 808,844 | 268,177 | 49.60% | 1,415,477,000 | Mar 31, 2023 |
| GREAT POINT PARTNERS LLC | 5.04% | 0.16% | 474,639 | 474,639 | 100.00% | 830,618,000 | Mar 31, 2023 |
| ALYESKA INVESTMENT GROUP, L.P. | 4.25% | 0.01% | 400,000 | 400,000 | 100.00% | 700,000,000 | Mar 31, 2023 |
| BRAIDWELL LP | 2.63% | 0.01% | 247,254 | 247,254 | 100.00% | 432,695,000 | Mar 31, 2023 |
| VANGUARD GROUP INC | 2.36% | - | 222,073 | - | - | 388,628,000 | Mar 31, 2023 |
| BLACKROCK INC. | 1.10% | - | 103,084 | -145 | -0.14% | 180,397,000 | Mar 31, 2023 |
| MAVEN SECURITIES LTD | 0.99% | 0.00% | 92,937 | 92,937 | 100.00% | 162,640,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 0.66% | 0.00% | 62,319 | 19,126 | 44.28% | 109,000 | Mar 31, 2023 |
| MONASHEE INVESTMENT MANAGEMENT LLC | 0.64% | 0.03% | 60,000 | 60,000 | 100.00% | 105,000,000 | Mar 31, 2023 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.55% | - | 51,332 | - | - | 89,831,000 | Mar 31, 2023 |
| GOLDMAN SACHS GROUP INC | 0.34% | - | 32,261 | -847 | -2.56% | 56,457,000 | Mar 31, 2023 |
| STATE STREET CORP | 0.27% | - | 25,643 | - | - | 44,875,000 | Mar 31, 2023 |
| MORGAN STANLEY | 0.13% | - | 12,326 | -99 | -0.80% | 21,571,000 | Mar 31, 2023 |
| NORTHERN TRUST CORP | 0.12% | - | 10,836 | -19 | -0.17% | 18,963,000 | Mar 31, 2023 |
| BANK OF AMERICA CORP /DE/ | 0.05% | - | 4,308 | 4,298 | 42980.00% | 7,539,000 | Mar 31, 2023 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.03% | 0.00% | 2,503 | 2,503 | 100.00% | 4,000 | Mar 31, 2023 |
| UBS GROUP AG | 0.03% | - | 2,350 | -3,827 | -61.96% | 4,113,000 | Mar 31, 2023 |
Avalo Therapeutics's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 46.93% of the company's total share outstanding, currently valued at $7.73B. The top 10 institutional shareholders own together 94.22% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VR ADVISER, LLC | 10.63% | 0.34% | 1,000,000 | 1,000,000 | 100.00% | 1,750,000,000 | Mar 31, 2023 |
| GREAT POINT PARTNERS LLC | 5.04% | 0.16% | 474,639 | 474,639 | 100.00% | 830,618,000 | Mar 31, 2023 |
| ARMISTICE CAPITAL, LLC | 46.93% | 0.11% | 4,415,000 | 450,334 | 11.36% | 7,726,250,000 | Mar 31, 2023 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 8.60% | 0.11% | 808,844 | 268,177 | 49.60% | 1,415,477,000 | Mar 31, 2023 |
| MONASHEE INVESTMENT MANAGEMENT LLC | 0.64% | 0.03% | 60,000 | 60,000 | 100.00% | 105,000,000 | Mar 31, 2023 |
| BRAIDWELL LP | 2.63% | 0.01% | 247,254 | 247,254 | 100.00% | 432,695,000 | Mar 31, 2023 |
| ALYESKA INVESTMENT GROUP, L.P. | 4.25% | 0.01% | 400,000 | 400,000 | 100.00% | 700,000,000 | Mar 31, 2023 |
| POINT72 ASSET MANAGEMENT, L.P. | 11.70% | 0.01% | 1,100,737 | 600,000 | 119.82% | 1,926,290,000 | Mar 31, 2023 |
| MAVEN SECURITIES LTD | 0.99% | 0.00% | 92,937 | 92,937 | 100.00% | 162,640,000 | Mar 31, 2023 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.03% | 0.00% | 2,503 | 2,503 | 100.00% | 4,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 0.66% | 0.00% | 62,319 | 19,126 | 44.28% | 109,000 | Mar 31, 2023 |
| TCI WEALTH ADVISORS, INC. | 0.00% | 0.00% | 251 | - | - | 440,000 | Mar 31, 2023 |
| FIRST HORIZON ADVISORS, INC. | 0.00% | - | 276 | 276 | 100.00% | 483,000 | Mar 31, 2023 |
| GOLDMAN SACHS GROUP INC | 0.34% | - | 32,261 | -847 | -2.56% | 56,457,000 | Mar 31, 2023 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.55% | - | 51,332 | - | - | 89,831,000 | Mar 31, 2023 |
| VANGUARD GROUP INC | 2.36% | - | 222,073 | - | - | 388,628,000 | Mar 31, 2023 |
| NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 0.00% | - | 10 | - | - | 18,000 | Mar 31, 2023 |
| MEEDER ASSET MANAGEMENT INC | 0.00% | - | 62 | -1,445 | -95.89% | 109,000 | Mar 31, 2023 |
| BLACKROCK INC. | 1.10% | - | 103,084 | -145 | -0.14% | 180,397,000 | Mar 31, 2023 |
| NORTHERN TRUST CORP | 0.12% | - | 10,836 | -19 | -0.17% | 18,963,000 | Mar 31, 2023 |
The largest Avalo Therapeutics shareholder by % of total assets is VR ADVISER, LLC. The company owns 1.00M shares of Avalo Therapeutics (AVTX), representing 0.34% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VR ADVISER, LLC | 10.63% | 0.34% | 1,000,000 | 1,000,000 | 100.00% | 1,750,000,000 | Mar 31, 2023 |
| POINT72 ASSET MANAGEMENT, L.P. | 11.70% | 0.01% | 1,100,737 | 600,000 | 119.82% | 1,926,290,000 | Mar 31, 2023 |
| GREAT POINT PARTNERS LLC | 5.04% | 0.16% | 474,639 | 474,639 | 100.00% | 830,618,000 | Mar 31, 2023 |
| ARMISTICE CAPITAL, LLC | 46.93% | 0.11% | 4,415,000 | 450,334 | 11.36% | 7,726,250,000 | Mar 31, 2023 |
| ALYESKA INVESTMENT GROUP, L.P. | 4.25% | 0.01% | 400,000 | 400,000 | 100.00% | 700,000,000 | Mar 31, 2023 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 8.60% | 0.11% | 808,844 | 268,177 | 49.60% | 1,415,477,000 | Mar 31, 2023 |
| BRAIDWELL LP | 2.63% | 0.01% | 247,254 | 247,254 | 100.00% | 432,695,000 | Mar 31, 2023 |
| MAVEN SECURITIES LTD | 0.99% | 0.00% | 92,937 | 92,937 | 100.00% | 162,640,000 | Mar 31, 2023 |
| MONASHEE INVESTMENT MANAGEMENT LLC | 0.64% | 0.03% | 60,000 | 60,000 | 100.00% | 105,000,000 | Mar 31, 2023 |
| MILLENNIUM MANAGEMENT LLC | 0.66% | 0.00% | 62,319 | 19,126 | 44.28% | 109,000 | Mar 31, 2023 |
| BANK OF AMERICA CORP /DE/ | 0.05% | - | 4,308 | 4,298 | 42980.00% | 7,539,000 | Mar 31, 2023 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.03% | 0.00% | 2,503 | 2,503 | 100.00% | 4,000 | Mar 31, 2023 |
| ROYAL BANK OF CANADA | 0.01% | - | 1,263 | 847 | 203.61% | 2,000,000 | Mar 31, 2023 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 334 | 334 | 100.00% | 584,000 | Mar 31, 2023 |
| FIRST HORIZON ADVISORS, INC. | 0.00% | - | 276 | 276 | 100.00% | 483,000 | Mar 31, 2023 |
| WELLS FARGO & COMPANY/MN | 0.00% | - | 158 | 27 | 20.61% | 277,000 | Mar 31, 2023 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.00% | - | 6 | - | - | 10,000 | Mar 31, 2023 |
| PARALLEL ADVISORS, LLC | - | - | 1 | - | - | 2,000 | Mar 31, 2023 |
| KISTLER-TIFFANY COMPANIES, LLC | - | - | 2 | - | - | 4,000 | Mar 31, 2023 |
| STATE STREET CORP | 0.27% | - | 25,643 | - | - | 44,875,000 | Mar 31, 2023 |
As of Mar 31 2023, Avalo Therapeutics's largest institutional buyer is VR ADVISER, LLC. The company purchased 1.00M stocks of AVTX, valued at $1.75B.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -18,671 | -100.00% | - | Mar 31, 2023 |
| ASSENAGON ASSET MANAGEMENT S.A. | - | - | - | -15,646 | -100.00% | - | Mar 31, 2023 |
| UBS GROUP AG | 0.03% | - | 2,350 | -3,827 | -61.96% | 4,113,000 | Mar 31, 2023 |
| MEEDER ASSET MANAGEMENT INC | 0.00% | - | 62 | -1,445 | -95.89% | 109,000 | Mar 31, 2023 |
| GOLDMAN SACHS GROUP INC | 0.34% | - | 32,261 | -847 | -2.56% | 56,457,000 | Mar 31, 2023 |
| SIMPLEX TRADING, LLC | - | - | - | -200 | -100.00% | - | Mar 31, 2023 |
| BLACKROCK INC. | 1.10% | - | 103,084 | -145 | -0.14% | 180,397,000 | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | - | - | - | -100 | -100.00% | - | Mar 31, 2023 |
| MORGAN STANLEY | 0.13% | - | 12,326 | -99 | -0.80% | 21,571,000 | Mar 31, 2023 |
| CLEARSTEAD ADVISORS, LLC | - | - | - | -27 | -100.00% | - | Mar 31, 2023 |
| NORTHERN TRUST CORP | 0.12% | - | 10,836 | -19 | -0.17% | 18,963,000 | Mar 31, 2023 |
| FMR LLC | - | - | - | -13 | -100.00% | - | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | 0.00% | - | 174 | -9 | -4.92% | 305,000 | Mar 31, 2023 |
| TCI WEALTH ADVISORS, INC. | 0.00% | 0.00% | 251 | - | - | 440,000 | Mar 31, 2023 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.55% | - | 51,332 | - | - | 89,831,000 | Mar 31, 2023 |
| VANGUARD GROUP INC | 2.36% | - | 222,073 | - | - | 388,628,000 | Mar 31, 2023 |
| NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 0.00% | - | 10 | - | - | 18,000 | Mar 31, 2023 |
| STATE STREET CORP | 0.27% | - | 25,643 | - | - | 44,875,000 | Mar 31, 2023 |
| KISTLER-TIFFANY COMPANIES, LLC | - | - | 2 | - | - | 4,000 | Mar 31, 2023 |
| PARALLEL ADVISORS, LLC | - | - | 1 | - | - | 2,000 | Mar 31, 2023 |
As of Mar 31 2023, Avalo Therapeutics's biggest institutional seller is SUSQUEHANNA INTERNATIONAL GROUP, LLP. The company sold -18.67K shares of AVTX, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VR ADVISER, LLC | 10.63% | 0.34% | 1,000,000 | 1,000,000 | 100.00% | 1,750,000,000 | Mar 31, 2023 |
| GREAT POINT PARTNERS LLC | 5.04% | 0.16% | 474,639 | 474,639 | 100.00% | 830,618,000 | Mar 31, 2023 |
| ALYESKA INVESTMENT GROUP, L.P. | 4.25% | 0.01% | 400,000 | 400,000 | 100.00% | 700,000,000 | Mar 31, 2023 |
| BRAIDWELL LP | 2.63% | 0.01% | 247,254 | 247,254 | 100.00% | 432,695,000 | Mar 31, 2023 |
| MAVEN SECURITIES LTD | 0.99% | 0.00% | 92,937 | 92,937 | 100.00% | 162,640,000 | Mar 31, 2023 |
| MONASHEE INVESTMENT MANAGEMENT LLC | 0.64% | 0.03% | 60,000 | 60,000 | 100.00% | 105,000,000 | Mar 31, 2023 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.03% | 0.00% | 2,503 | 2,503 | 100.00% | 4,000 | Mar 31, 2023 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 334 | 334 | 100.00% | 584,000 | Mar 31, 2023 |
| FIRST HORIZON ADVISORS, INC. | 0.00% | - | 276 | 276 | 100.00% | 483,000 | Mar 31, 2023 |
Avalo Therapeutics's largest new institutional shareholder by number of shares is VR ADVISER, LLC, purchased 1.00M shares, valued at $1.75B, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -18,671 | -100.00% | - | Mar 31, 2023 |
| ASSENAGON ASSET MANAGEMENT S.A. | - | - | - | -15,646 | -100.00% | - | Mar 31, 2023 |
| SIMPLEX TRADING, LLC | - | - | - | -200 | -100.00% | - | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | - | - | - | -100 | -100.00% | - | Mar 31, 2023 |
| CLEARSTEAD ADVISORS, LLC | - | - | - | -27 | -100.00% | - | Mar 31, 2023 |
| FMR LLC | - | - | - | -13 | -100.00% | - | Mar 31, 2023 |
Avalo Therapeutics's largest sold out institutional shareholder by shares sold is SUSQUEHANNA INTERNATIONAL GROUP, LLP, sold -18.67K shares, valued at -, as of undefined.
Avalo Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 8,757 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 81,296 | - | - | Mar 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 2,050 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.01% | 4,279 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 2,708,030 | - | - | Mar 31, 2024 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 237,319 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 805,083 | - | - | Feb 29, 2024 |
| Meeder Funds | 0.00% | 18,082 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 135,369 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 306,283 | - | - | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 43,145 | - | - | Mar 31, 2024 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 5,200 | - | - | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 3,683 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 1,893 | - | - | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 19,776 | - | - | Mar 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 1,640 | - | - | Mar 31, 2024 |
| Global X Funds | 0.00% | 17,531 | - | - | Jan 31, 2024 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 19,776 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 32,361 | - | - | Mar 28, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 242,233 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 2,306 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 11,200 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 72,041 | - | - | Mar 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 593 | - | - | Dec 31, 2023 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 3,596 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 4,746 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 1,333 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 136,576 | - | - | Mar 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 452,820 | - | - | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 206,431 | - | - | Feb 29, 2024 |
| HC CAPITAL TRUST | 0.00% | 3,007 | - | - | Mar 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 11,698 | - | - | Mar 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 329 | - | - | Dec 31, 2023 |
| VALIC Co I | 0.00% | 23,093 | - | - | Feb 29, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 1,654 | - | - | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 15,370 | - | - | Jan 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 362 | - | - | Feb 29, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 3,500 | - | - | Mar 31, 2023 |
| TIAA-CREF FUNDS | 0.00% | 159,124 | - | - | Mar 31, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 59 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 5,393 | - | - | Jan 31, 2024 |
| PROSHARES TRUST | 0.00% | 8,970 | - | - | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,000 | - | - | Mar 28, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 6,352 | 6,352 | - | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 2,121 | - | - | Feb 29, 2024 |
| ETF Series Solutions | 0.00% | 416 | - | - | Jan 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 6,870 | - | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 42,200 | - | - | Mar 31, 2024 |
| Meeder Funds | 0.00% | 62 | - | - | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 19,453 | - | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 5,371 | - | - | Dec 31, 2023 |
| Guggenheim Active Allocation Fund | 0.00% | 30 | - | - | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 972 | - | - | Jan 31, 2024 |
| iSHARES TRUST | 0.00% | 63,768 | - | - | Mar 31, 2024 |
| Bridge Builder Trust | 0.00% | 9,229 | - | - | Mar 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 7,166 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 9,853 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 3,324 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 1,583 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 302 | -298 | -49.70% | Mar 31, 2024 |
| BLACKROCK FUNDS | 0.00% | 3,381 | - | - | Mar 28, 2024 |
| iSHARES TRUST | 0.00% | 4,876 | - | - | Mar 31, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 5,300 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 362 | - | - | Mar 31, 2024 |
Avalo Therapeutics's largest mutual fund holder by % of total assets is "DEUTSCHE DWS INVESTMENTS VIT FUNDS", owning 8.76K shares, compromising 0.01% of its total assets.
Avalo Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 22 | 42 | -34.38% |
| 31 Mar, 22 | 64 | -12.33% |
| 31 Dec, 21 | 73 | -3.95% |
| 30 Sep, 21 | 76 | - |
As of 30 Jun 22, 42 institutions are holding Avalo Therapeutics's shares, representing a decrease of -34.38% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 22 | 69,378,775 | -10.69% |
| 31 Mar, 22 | 77,679,178 | -2.87% |
| 31 Dec, 21 | 79,978,021 | -0.58% |
| 30 Sep, 21 | 80,445,353 | - |
Avalo Therapeutics (AVTX) has 69.38M shares outstanding as of 30 Jun 22, down -10.69% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 22 | 61.50% | 1.30% |
| 31 Mar, 22 | 68.87% | 1.09% |
| 31 Dec, 21 | 79.59% | 1.24% |
| 30 Sep, 21 | 80.05% | - |
As of 30 Jun 22, Avalo Therapeutics is held by 61.50% institutional shareholders, representing a 1.30% growth compared to 31 Mar 22.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 22 | 14 | -30.00% |
| 31 Mar, 22 | 20 | -52.38% |
| 31 Dec, 21 | 42 | -42.47% |
| 30 Sep, 21 | 73 | - |
14 institutional shareholders have increased their position in AVTX stock as of 30 Jun 22 compared to 20 in the previous quarter (a -30.00% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 22 | 19 | -32.14% |
| 31 Mar, 22 | 28 | 86.67% |
| 31 Dec, 21 | 15 | - |
| 30 Sep, 21 | - | - |
19 institutional shareholders have reduced their position in AVTX stock as of 30 Jun 22 compared to 28 in the previous quarter (a -32.14% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 22 | 42 | -34.38% | 69,378,775 | -10.69% | 61.50% | 1.30% | 14 | -30.00% | 19 | -32.14% |
| 31 Mar, 22 | 64 | -12.33% | 77,679,178 | -2.87% | 68.87% | 1.09% | 20 | -52.38% | 28 | 86.67% |
| 31 Dec, 21 | 73 | -3.95% | 79,978,021 | -0.58% | 79.59% | 1.24% | 42 | -42.47% | 15 | - |
| 30 Sep, 21 | 76 | - | 80,445,353 | - | 80.05% | - | 73 | - | - | - |
Avalo Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
All Insider Owners Trades
Avalo Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 17 | - | - |
| Q2 2024 | 1 | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | 4 | - | - |
| Q2 2023 | 38 | 4 | 950.00% |
| Q1 2023 | 7 | - | - |
| Q4 2022 | 5 | - | - |
| Q3 2022 | 3 | - | - |
| Q2 2022 | 14 | - | - |
| Q1 2022 | 28 | - | - |
| Q4 2021 | 12 | - | - |
| Q3 2021 | 12 | - | - |
| Q2 2021 | 24 | 1 | 2400.00% |
| Q1 2021 | 13 | 4 | 325.00% |
| Q4 2020 | 17 | - | - |
| Q3 2020 | 7 | - | - |
| Q2 2020 | 23 | 5 | 460.00% |
| Q1 2020 | 23 | 4 | 575.00% |
| Q4 2019 | 6 | - | - |
| Q3 2019 | 24 | 1 | 2400.00% |
17 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Avalo Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | - | - |
| Q2 2024 | - | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | - | - | - |
| Q2 2023 | 36 | 2 | 1800.00% |
| Q1 2023 | 2 | - | - |
| Q4 2022 | 1 | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | 16 | - | - |
| Q4 2021 | 5 | - | - |
| Q3 2021 | 6 | - | - |
| Q2 2021 | 10 | - | - |
| Q1 2021 | 2 | - | - |
| Q4 2020 | 11 | - | - |
| Q3 2020 | 2 | - | - |
| Q2 2020 | 10 | - | - |
| Q1 2020 | 13 | - | - |
| Q4 2019 | 3 | - | - |
| Q3 2019 | 15 | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Avalo Therapeutics's stocks.
Avalo Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| ANAB | AnaptysBio, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ALZN | Alzamend Neuro, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| ALXO | ALX Oncology Holdings Inc. |
| CCCC | C4 Therapeutics, Inc. |
| VRAX | Virax Biolabs Group Limited |
| ACLX | Arcellx, Inc. |
| GPCR | Structure Therapeutics Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| BNOX | Bionomics Limited |
| MOLN | Molecular Partners AG |
| BNTC | Benitec Biopharma Inc. |
AVTX Ownership FAQ
Who Owns Avalo Therapeutics?
Avalo Therapeutics is owned by institutional shareholders (61.50%), insiders (16.46%), and public (22.04%). The largest institutional shareholder of Avalo Therapeutics is ARMISTICE CAPITAL, LLC (46.93% of total shares) and the top mutual fund owner is DEUTSCHE DWS INVESTMENTS VIT FUNDS (0.01% of total shares).
Who are the major institutional shareholders of Avalo Therapeutics?
Avalo Therapeutics's major institutional shareholders are ARMISTICE CAPITAL, LLC, POINT72 ASSET MANAGEMENT, L.P., VR ADVISER, LLC, NANTAHALA CAPITAL MANAGEMENT, LLC, and GREAT POINT PARTNERS LLC. The top five shareholders own together 82.90% of the company's share outstanding.
How many Avalo Therapeutics shareholders are there?
As of Jun 2022, there are 42 institutional shareholders of Avalo Therapeutics.
What percentage of Avalo Therapeutics is owned by ARMISTICE CAPITAL, LLC?
ARMISTICE CAPITAL, LLC owns 4.42M shares of Avalo Therapeutics, representing 46.93% of the company's total shares outstanding, valued at $7.73B (as of Mar 2023).
What percentage of Avalo Therapeutics is owned by POINT72 ASSET MANAGEMENT, L.P?
As of Mar 2023, POINT72 ASSET MANAGEMENT, L.P holds 1.1M shares of Avalo Therapeutics (AVTX), compromising 11.70% of the company, valued at $1.93B.
What percentage of Avalo Therapeutics is owned by VR ADVISER, LLC?
VR ADVISER, LLC is the third largest holder of Avalo Therapeutics. The company owns 1M of the company's shares outstanding (worth $1.75B).